User profiles for Nicole A. P. Lieberman
Nicole LiebermanSenior Scientist, University of Washington Verified email at uw.edu Cited by 1708 |
[HTML][HTML] In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age
Despite limited genomic diversity, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has shown a wide range of clinical manifestations in different patient populations. …
has shown a wide range of clinical manifestations in different patient populations. …
Genetically engineered macrophages: a potential platform for cancer immunotherapy
KW Moyes, NAP Lieberman, SA Kreuser… - Human gene …, 2017 - liebertpub.com
In spite of their successes against hematologic malignancies, immunotherapeutic interventions
for the treatment of patients with glioblastoma (GBM) have thus far been unsuccessful. …
for the treatment of patients with glioblastoma (GBM) have thus far been unsuccessful. …
SARS-CoV-2 ORF6 disrupts bidirectional nucleocytoplasmic transport through interactions with Rae1 and Nup98
RNA viruses that replicate in the cytoplasm often disrupt nucleocytoplasmic transport to
preferentially translate their own transcripts and prevent host antiviral responses. The …
preferentially translate their own transcripts and prevent host antiviral responses. The …
Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy
NAP Lieberman, K DeGolier, HM Kovar… - Neuro …, 2019 - academic.oup.com
Background Diffuse intrinsic pontine glioma (DIPG) is a uniformly fatal CNS tumor diagnosed
in 300 American children per year. Radiation is the only effective treatment and extends …
in 300 American children per year. Radiation is the only effective treatment and extends …
[HTML][HTML] Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection
…, D Decimo, M Iampietro, NAP Lieberman… - Nature …, 2021 - nature.com
SARS-CoV-2 has caused a global pandemic of COVID-19 since its emergence in December
2019. The infection causes a severe acute respiratory syndrome and may also spread to …
2019. The infection causes a severe acute respiratory syndrome and may also spread to …
Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain
…, Y Zhu, MJ Lin, A Addetia, NAP Lieberman… - MBio, 2020 - Am Soc Microbiol
The emergence of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2),
the etiological agent of the 2019 coronavirus disease (COVID-19), has erupted into a global …
the etiological agent of the 2019 coronavirus disease (COVID-19), has erupted into a global …
[HTML][HTML] Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir
and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials …
and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials …
Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
gravely affected societies around the world. Outbreaks in different parts of the globe have been …
gravely affected societies around the world. Outbreaks in different parts of the globe have been …
[HTML][HTML] Treponema pallidum genome sequencing from six continents reveals variability in vaccine candidate genes and dominance of Nichols clade strains in …
NAP Lieberman, MJ Lin, H Xie, L Shrestha… - PLoS neglected …, 2021 - journals.plos.org
In spite of its immutable susceptibility to penicillin, Treponema pallidum (T. pallidum) subsp.
pallidum continues to cause millions of cases of syphilis each year worldwide, resulting in …
pallidum continues to cause millions of cases of syphilis each year worldwide, resulting in …
[HTML][HTML] Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
…, BM Prieskorn, NAP Lieberman… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Though currently approved immunotherapies, including chimeric antigen
receptor T cells and checkpoint blockade antibodies, have been successfully used to treat …
receptor T cells and checkpoint blockade antibodies, have been successfully used to treat …